Stacy Brown
Family · Mt Juliet, TNNPI 1093937872
Payments from drug & device makers
Across 1,951 payments — averaging $368.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$531K
- AstraZeneca$139K
- Novo Nordisk$30K
- Bayer$9K
- Esperion Therapeutics, Inc.$4K
- Corcept Therapeutics$2K
- plus $5K from 23 others
What the payments were for
- Speaking & faculty fees$486,15168%
- Travel & lodging$212,44830%
- Food & beverage$20,5193%
- Education$2240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 1,226 | $530,889 |
| AstraZeneca | 248 | $138,980 |
| Novo Nordisk | 111 | $30,062 |
| Bayer | 34 | $8,507 |
| Esperion Therapeutics, Inc. | 35 | $4,248 |
| Corcept Therapeutics | 45 | $1,868 |
| Sanofi-aventis U.S. LLC | 40 | $754 |
| Xeris Pharmaceuticals, Inc. | 39 | $657 |
| Abbott | 24 | $603 |
| Amgen | 38 | $562 |
| Insulet Corporation | 18 | $271 |
| Mannkind Corporation | 10 | $238 |
| Medtronic | 11 | $218 |
| Boehringer Ingelheim | 12 | $211 |
| Dexcom, Inc. | 12 | $204 |
| Tandem Diabetes Care, Inc. | 8 | $194 |
| BETA Bionics, Inc. | 9 | $170 |
| Sequel Med Tech, LLC | 6 | $156 |
| Zealand Pharma US, Inc. | 7 | $123 |
| Novartis | 6 | $103 |
| Ascensia Diabetes Care US Inc. | 1 | $86 |
| Cequr Corporation | 2 | $63 |
| Ascendis Pharma Endocrinology Inc | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| GSK | 1 | $25 |
| IBSA Pharma Inc. | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| AbbVie | 1 | $16 |
| Evoke Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$719,342 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 594 | $708,096 |
| OzempicSemaglutide | 306 | $387,920 |
| Tresiba Flextouch U-200Insulin Degludec | 194 | $249,937 |
| FarxigaDapagliflozin Propanediol | 260 | $223,252 |
| JardianceEmpagliflozin | 163 | $157,915 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 145 | $154,360 |
| TrulicityDulaglutide | 118 | $141,638 |
| Xigduo XrDapaglifloz Propaned/Metformin | 63 | $59,137 |
| GlyxambiEmpagliflozin/Linagliptin | 52 | $52,706 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 31 | $30,112 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $29,925 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $28,792 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 21 | $25,863 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 102 | $21,725 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 23 | $21,043 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $530,889 | $856,022753 claims |
| Novo NordiskOzempic, Rybelsus | $30,062 | $403,478317 claims |
| Boehringer IngelheimJardiance, Glyxambi, Synjardy Xr | $211 | $240,734246 claims |
| AstraZenecaFarxiga | $138,980 | $223,252260 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $754 | $14,90517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Mt Juliet
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
- Melissa RikalNashville$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.